Quality assurance initiative for the treatment of breast cancer in Germany

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00034286

Enrollment

2500

Registered

2024-05-28

Start date

2026-10-01

Completion date

Unknown

Last updated

2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C50

Interventions

Group 1: Early breast cancer (EBC): patients with HER2 positive breast cancer, triple-negative breast cancer or HER2 negative, hormone receptor positive breast cancer in UICC stage II or higher with s

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: EBC: HER2+, TNBC or HER2-/HR+ UICC II or higher; surgery between January and August 2026 MBC: drug-based tumor therapy in current line; start of treatment line no more than 6 months in ago (January 2026 or later)

Exclusion criteria

Exclusion criteria: Patients who are not receiving any drug-based tumor therapy in current primary therapy or in the current MBC treatment line; Patients who are treated exclusively with osteoprotectants

Design outcomes

Primary

Measure	Time frame
Implementation of the guideline recommendations in routine treatment	—

Secondary

Measure	Time frame
Well-founded, representative picture of the current therapeutic routine and the demographic and clinical characteristics of patients with early and metastatic breast cancer	—

Countries

Germany

Contacts

Public ContactPatrik Lindenmaier

MMF GmbH

lindenmaier@mmf-research.de+49 (251) 92873012

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Jun 11, 2026